Castleman Disease Treatment Market by Treatment Type (Chemotherapy, Corticosteroids, Siltuximab), Line Of Therapy (First Line, Later Lines, Second Line), Distribution Channel, End User - Global Forecast 2025-2032
Description
The Castleman Disease Treatment Market was valued at USD 334.15 million in 2024 and is projected to grow to USD 380.66 million in 2025, with a CAGR of 14.01%, reaching USD 954.52 million by 2032.
A detailed clinical orientation describing diagnostic complexity, therapeutic modalities, evolving evidence, and unmet patient and provider needs in Castleman disease
Castleman disease presents a heterogeneous set of clinical challenges that span diagnostic ambiguity, variable disease trajectories, and a complex therapeutic landscape. Patients often present with nonspecific symptoms that overlap with other inflammatory and hematologic disorders, and definitive diagnosis commonly requires an integration of histopathology, radiology, and clinical judgment. Recent advances in immunopathology and cytokine biology have clarified some disease mechanisms, yet significant gaps remain in early detection and standardized diagnostic pathways.
The treatment environment is characterized by a mix of targeted biologic agents, conventional systemic therapies, and supportive interventions tailored to disease subtype and severity. Evolving clinical practice now emphasizes individualized care plans that balance efficacy with long-term safety and quality-of-life considerations. Concurrently, regulatory activity and evolving reimbursement frameworks are shaping access to novel therapeutics, leading clinicians and payers to reassess treatment algorithms. Amid these shifts, stakeholders must navigate an increasingly interconnected ecosystem of diagnostics, therapeutics, and patient support services to improve outcomes and optimize resource allocation.
Critical transformational dynamics reshaping the therapeutic ecosystem for Castleman disease through science, commercial strategy, and payer-driven evidence requirements
The therapeutic and commercial landscape for Castleman disease has undergone transformative shifts driven by scientific, commercial, and policy developments. On the scientific front, deeper insights into cytokine signaling pathways and immune dysregulation have enabled the repositioning of targeted monoclonal antibodies and complementary biologics. These advances are reshaping treatment algorithms and moving the field away from one-size-fits-all approaches toward precision-informed regimens that account for phenotype and disease drivers.
Commercially, the ecosystem has trended toward strategic partnerships, cross-disciplinary collaborations, and a heightened focus on real-world evidence generation. Pharmaceutical developers are investing in robust post-approval evidence programs and clinician education to demonstrate long-term benefit and optimize adoption. At the same time, payers are increasingly demanding comparative effectiveness and value demonstration, prompting manufacturers to refine pricing, access, and outcomes-based contracting strategies. Consequently, providers, patients, and payers are adapting to a more evidence-driven, patient-centric model that emphasizes durable responses, safety, and cost-effective care pathways.
Comprehensive analysis of the 2025 United States tariff changes and their cascading effects on supply chains, procurement, clinical trials, and access for Castleman disease therapies
Recent tariff measures in the United States introduced in 2025 have created notable supply chain friction for imported biologics, specialized reagents, and certain medical consumables that are integral to Castleman disease diagnosis and treatment delivery. Manufacturers and distributors experienced immediate increases in landed costs for selected components, prompting some suppliers to explore alternative sourcing strategies or to accelerate domestic production of critical inputs. As a result, procurement teams faced shorter-term volatility in supplier pricing and lead times, which, in turn, affected inventory planning and clinical service continuity.
Clinical trial operations and investigator-initiated research experienced heightened protocol risk where investigational therapies relied on components subject to import duties. Sponsors responded by negotiating revised vendor contracts, adjusting logistics corridors, and prioritizing regulatory compliance in cross-border shipments. Meanwhile, healthcare providers and specialty pharmacies reassessed formulary procurement practices to maintain uninterrupted patient access, often engaging in bilateral negotiations with manufacturers and third-party logistics providers. In parallel, some upstream manufacturers increased investment in regional manufacturing capacity to mitigate future tariff exposure, thereby influencing long-term supply resilience and sourcing strategies across the ecosystem.
In-depth segmentation-driven insight connecting treatment types, therapeutic sequencing, distribution pathways, and care settings to inform clinical and commercial decision-making
A nuanced segmentation analysis reveals how treatment modalities, lines of therapy, distribution pathways, and end-user settings intersect to shape clinical practice and commercial strategy. Based on Treatment Type, the therapeutic landscape is observed across Chemotherapy, Corticosteroids, Siltuximab, and Tocilizumab. Within Chemotherapy, distinctions between Combination Therapy and Monotherapy influence toxicity management and supportive care needs, while within Corticosteroids, agents such as Dexamethasone and Prednisone present different pharmacologic profiles and tapering considerations that affect patient adherence and long-term outcomes. These intra-class differences inform formulary decisions and clinician selection of adjunctive therapies.
Based on Line Of Therapy, patient journeys are classified into First Line, Later Lines, and Second Line, with First Line further differentiated by Combination Therapy and Monotherapy approaches. This segmentation clarifies decision points for escalation, de-escalation, and sequencing of agents, and highlights opportunities for interventions that may alter disease trajectory earlier in care. Based on Distribution Channel, treatment access pathways fall between Offline and Online channels, each with distinct implications for dispensing practices, telehealth integration, and patient support services. Based on End User, care is delivered in Home Care Settings, Hospitals, and Specialty Clinics, where Home Care Settings further subdivide into Self Administration and Visiting Nurse Services. These delivery environments influence adherence, monitoring intensity, and resource allocation, and they suggest differentiated support models to enhance treatment persistence and patient experience.
Regional strategic imperatives and differentiated access dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific shaping Castleman disease care delivery and evidence needs
Regional dynamics exert strong influence over clinical practice, regulatory pathways, and access architectures for Castleman disease therapies, creating differentiated strategic priorities across geographic corridors. In the Americas, advanced diagnostic infrastructure and established specialty care networks facilitate earlier specialist referral and broader adoption of targeted biologics, yet payers demand robust evidence of comparative effectiveness and long-term benefit. Consequently, stakeholders in this region prioritize clinical-genomic integration, outcomes data generation, and value-based contracting.
In Europe, Middle East & Africa, heterogeneity in regulatory frameworks, reimbursement systems, and care delivery capacity leads to a fragmented access landscape. Some jurisdictions have centralized assessment pathways that expedite access for high-need therapies, while others face resource constraints that limit specialist availability. This variation compels manufacturers to tailor launch sequencing and patient support models to local payer and provider requirements. In the Asia-Pacific region, rapid investments in manufacturing capability, biologics adoption, and specialty care networks are changing the competitive calculus. Providers and governments are increasingly focused on building domestic capabilities, reducing import dependence, and expanding access through public-private collaborations. Across regions, strategic priorities converge around improving diagnostic accuracy, strengthening supply chains, and generating regionally relevant evidence to support reimbursement decisions.
Company-level strategies prioritizing clinical differentiation, manufacturing resilience, and integrated access solutions to sustain treatment continuity and payer alignment
Key company-level behaviors reveal an emphasis on therapeutic differentiation, manufacturing resilience, and collaborative ecosystems to deliver sustainable patient access. Leading developers are refining clinical development programs to emphasize durable responses and safety profiles that matter to clinicians and payers, while also building comprehensive post-approval evidence strategies that include registries and real-world treatment outcome measurement. These efforts strengthen clinical value propositions and support negotiations with payers and health systems.
From an operational perspective, organizations are investing in supply chain redundancy, regional manufacturing, and cold-chain logistics to protect continuity of biologic supply. In parallel, commercial teams are developing tailored access solutions that integrate patient education, nursing support, and hub services to simplify treatment initiation and adherence. Strategic partnerships with diagnostic providers, contract research organizations, and specialty pharmacies extend the capability set necessary to optimize diagnosis-to-treatment pathways. Finally, several companies are exploring outcome-linked contracting and risk-sharing arrangements with purchasers to align payment with demonstrated clinical benefit, reflecting a pragmatic response to payer demands for long-term value assurance.
Practical strategic recommendations for advancing diagnostic clarity, evidence generation, supply resilience, and payer-aligned access models in Castleman disease therapeutics
Industry leaders should pursue a set of actionable strategies that align scientific innovation with pragmatic access planning and evidence generation to maximize therapeutic impact and patient benefit. First, prioritize investment in diagnostic clarity by supporting initiatives that standardize histopathologic interpretation and biomarker-driven decision-making, thereby reducing diagnostic delay and enabling more targeted therapeutic use. Second, structure clinical programs and post-approval evidence plans to capture meaningful real-world outcomes that resonate with payers and clinicians, focusing on durability of response, steroid-sparing effects, and health-related quality of life.
Third, reinforce supply chain resilience by diversifying suppliers, qualifying regional manufacturing partners, and instituting flexible logistics pathways that can adapt to tariff or trade disruptions. Fourth, build differentiated access models that integrate specialty pharmacy services, home-based care options, and educational interventions to reduce initiation friction and support long-term adherence. Fifth, engage proactively with payers to explore outcomes-based contracting where appropriate, and develop transparent value dossiers that align clinical benefits with economic considerations. Taken together, these actions will support sustainable adoption while protecting patient access and promoting high-quality care.
A transparent multi-method research framework incorporating expert interviews, literature synthesis, real-world evidence analysis, and supply chain and policy review to ensure robust conclusions
The research approach combines multiple complementary methods to produce a comprehensive and defensible evidence base. Primary research consisted of structured interviews with clinical experts, specialty pharmacists, payers, and supply chain managers to capture frontline perspectives on diagnosis, treatment selection, and access barriers. These qualitative insights were triangulated with an exhaustive review of peer-reviewed literature, regulatory filings, clinical trial portals, and publicly available treatment guidelines to ensure alignment with the most current scientific and regulatory context.
In addition, real-world data sources and anonymized treatment registries were analyzed to identify patterns in therapy utilization, treatment discontinuation, and care setting preferences. Supply chain mapping and policy analysis were used to evaluate the implications of trade measures and procurement dynamics. Throughout the process, methodological rigor was maintained via transparent inclusion criteria, interviewer training, and consistency checks, and findings were validated in follow-up consultations with independent clinicians and payer advisors to mitigate bias and confirm practical relevance.
A concise synthesizing conclusion highlighting coordinated clinical, commercial, and operational priorities required to translate scientific advances into equitable patient outcomes
In conclusion, the Castleman disease landscape is at an inflection point where improved biological understanding and targeted therapies are intersecting with heightened payer scrutiny and supply chain complexity. Clinical practice is evolving toward precision-informed regimens supported by stronger evidence generation and integrated care models. At the same time, trade dynamics and procurement pressures are prompting stakeholders to rethink sourcing, manufacturing, and distribution approaches to preserve access and manage cost volatility.
Moving forward, success will require coordination across clinical, commercial, and operational domains. By investing in diagnostic standardization, durable evidence generation, resilient supply chains, and payer-aligned access strategies, stakeholders can reduce barriers to care while ensuring that treatments deliver meaningful, lasting benefits for patients. The collective actions of developers, providers, and payers will determine whether the promise of recent scientific advances translates into consistent, equitable outcomes for people living with Castleman disease.
Please Note: PDF & Excel + Online Access - 1 Year
A detailed clinical orientation describing diagnostic complexity, therapeutic modalities, evolving evidence, and unmet patient and provider needs in Castleman disease
Castleman disease presents a heterogeneous set of clinical challenges that span diagnostic ambiguity, variable disease trajectories, and a complex therapeutic landscape. Patients often present with nonspecific symptoms that overlap with other inflammatory and hematologic disorders, and definitive diagnosis commonly requires an integration of histopathology, radiology, and clinical judgment. Recent advances in immunopathology and cytokine biology have clarified some disease mechanisms, yet significant gaps remain in early detection and standardized diagnostic pathways.
The treatment environment is characterized by a mix of targeted biologic agents, conventional systemic therapies, and supportive interventions tailored to disease subtype and severity. Evolving clinical practice now emphasizes individualized care plans that balance efficacy with long-term safety and quality-of-life considerations. Concurrently, regulatory activity and evolving reimbursement frameworks are shaping access to novel therapeutics, leading clinicians and payers to reassess treatment algorithms. Amid these shifts, stakeholders must navigate an increasingly interconnected ecosystem of diagnostics, therapeutics, and patient support services to improve outcomes and optimize resource allocation.
Critical transformational dynamics reshaping the therapeutic ecosystem for Castleman disease through science, commercial strategy, and payer-driven evidence requirements
The therapeutic and commercial landscape for Castleman disease has undergone transformative shifts driven by scientific, commercial, and policy developments. On the scientific front, deeper insights into cytokine signaling pathways and immune dysregulation have enabled the repositioning of targeted monoclonal antibodies and complementary biologics. These advances are reshaping treatment algorithms and moving the field away from one-size-fits-all approaches toward precision-informed regimens that account for phenotype and disease drivers.
Commercially, the ecosystem has trended toward strategic partnerships, cross-disciplinary collaborations, and a heightened focus on real-world evidence generation. Pharmaceutical developers are investing in robust post-approval evidence programs and clinician education to demonstrate long-term benefit and optimize adoption. At the same time, payers are increasingly demanding comparative effectiveness and value demonstration, prompting manufacturers to refine pricing, access, and outcomes-based contracting strategies. Consequently, providers, patients, and payers are adapting to a more evidence-driven, patient-centric model that emphasizes durable responses, safety, and cost-effective care pathways.
Comprehensive analysis of the 2025 United States tariff changes and their cascading effects on supply chains, procurement, clinical trials, and access for Castleman disease therapies
Recent tariff measures in the United States introduced in 2025 have created notable supply chain friction for imported biologics, specialized reagents, and certain medical consumables that are integral to Castleman disease diagnosis and treatment delivery. Manufacturers and distributors experienced immediate increases in landed costs for selected components, prompting some suppliers to explore alternative sourcing strategies or to accelerate domestic production of critical inputs. As a result, procurement teams faced shorter-term volatility in supplier pricing and lead times, which, in turn, affected inventory planning and clinical service continuity.
Clinical trial operations and investigator-initiated research experienced heightened protocol risk where investigational therapies relied on components subject to import duties. Sponsors responded by negotiating revised vendor contracts, adjusting logistics corridors, and prioritizing regulatory compliance in cross-border shipments. Meanwhile, healthcare providers and specialty pharmacies reassessed formulary procurement practices to maintain uninterrupted patient access, often engaging in bilateral negotiations with manufacturers and third-party logistics providers. In parallel, some upstream manufacturers increased investment in regional manufacturing capacity to mitigate future tariff exposure, thereby influencing long-term supply resilience and sourcing strategies across the ecosystem.
In-depth segmentation-driven insight connecting treatment types, therapeutic sequencing, distribution pathways, and care settings to inform clinical and commercial decision-making
A nuanced segmentation analysis reveals how treatment modalities, lines of therapy, distribution pathways, and end-user settings intersect to shape clinical practice and commercial strategy. Based on Treatment Type, the therapeutic landscape is observed across Chemotherapy, Corticosteroids, Siltuximab, and Tocilizumab. Within Chemotherapy, distinctions between Combination Therapy and Monotherapy influence toxicity management and supportive care needs, while within Corticosteroids, agents such as Dexamethasone and Prednisone present different pharmacologic profiles and tapering considerations that affect patient adherence and long-term outcomes. These intra-class differences inform formulary decisions and clinician selection of adjunctive therapies.
Based on Line Of Therapy, patient journeys are classified into First Line, Later Lines, and Second Line, with First Line further differentiated by Combination Therapy and Monotherapy approaches. This segmentation clarifies decision points for escalation, de-escalation, and sequencing of agents, and highlights opportunities for interventions that may alter disease trajectory earlier in care. Based on Distribution Channel, treatment access pathways fall between Offline and Online channels, each with distinct implications for dispensing practices, telehealth integration, and patient support services. Based on End User, care is delivered in Home Care Settings, Hospitals, and Specialty Clinics, where Home Care Settings further subdivide into Self Administration and Visiting Nurse Services. These delivery environments influence adherence, monitoring intensity, and resource allocation, and they suggest differentiated support models to enhance treatment persistence and patient experience.
Regional strategic imperatives and differentiated access dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific shaping Castleman disease care delivery and evidence needs
Regional dynamics exert strong influence over clinical practice, regulatory pathways, and access architectures for Castleman disease therapies, creating differentiated strategic priorities across geographic corridors. In the Americas, advanced diagnostic infrastructure and established specialty care networks facilitate earlier specialist referral and broader adoption of targeted biologics, yet payers demand robust evidence of comparative effectiveness and long-term benefit. Consequently, stakeholders in this region prioritize clinical-genomic integration, outcomes data generation, and value-based contracting.
In Europe, Middle East & Africa, heterogeneity in regulatory frameworks, reimbursement systems, and care delivery capacity leads to a fragmented access landscape. Some jurisdictions have centralized assessment pathways that expedite access for high-need therapies, while others face resource constraints that limit specialist availability. This variation compels manufacturers to tailor launch sequencing and patient support models to local payer and provider requirements. In the Asia-Pacific region, rapid investments in manufacturing capability, biologics adoption, and specialty care networks are changing the competitive calculus. Providers and governments are increasingly focused on building domestic capabilities, reducing import dependence, and expanding access through public-private collaborations. Across regions, strategic priorities converge around improving diagnostic accuracy, strengthening supply chains, and generating regionally relevant evidence to support reimbursement decisions.
Company-level strategies prioritizing clinical differentiation, manufacturing resilience, and integrated access solutions to sustain treatment continuity and payer alignment
Key company-level behaviors reveal an emphasis on therapeutic differentiation, manufacturing resilience, and collaborative ecosystems to deliver sustainable patient access. Leading developers are refining clinical development programs to emphasize durable responses and safety profiles that matter to clinicians and payers, while also building comprehensive post-approval evidence strategies that include registries and real-world treatment outcome measurement. These efforts strengthen clinical value propositions and support negotiations with payers and health systems.
From an operational perspective, organizations are investing in supply chain redundancy, regional manufacturing, and cold-chain logistics to protect continuity of biologic supply. In parallel, commercial teams are developing tailored access solutions that integrate patient education, nursing support, and hub services to simplify treatment initiation and adherence. Strategic partnerships with diagnostic providers, contract research organizations, and specialty pharmacies extend the capability set necessary to optimize diagnosis-to-treatment pathways. Finally, several companies are exploring outcome-linked contracting and risk-sharing arrangements with purchasers to align payment with demonstrated clinical benefit, reflecting a pragmatic response to payer demands for long-term value assurance.
Practical strategic recommendations for advancing diagnostic clarity, evidence generation, supply resilience, and payer-aligned access models in Castleman disease therapeutics
Industry leaders should pursue a set of actionable strategies that align scientific innovation with pragmatic access planning and evidence generation to maximize therapeutic impact and patient benefit. First, prioritize investment in diagnostic clarity by supporting initiatives that standardize histopathologic interpretation and biomarker-driven decision-making, thereby reducing diagnostic delay and enabling more targeted therapeutic use. Second, structure clinical programs and post-approval evidence plans to capture meaningful real-world outcomes that resonate with payers and clinicians, focusing on durability of response, steroid-sparing effects, and health-related quality of life.
Third, reinforce supply chain resilience by diversifying suppliers, qualifying regional manufacturing partners, and instituting flexible logistics pathways that can adapt to tariff or trade disruptions. Fourth, build differentiated access models that integrate specialty pharmacy services, home-based care options, and educational interventions to reduce initiation friction and support long-term adherence. Fifth, engage proactively with payers to explore outcomes-based contracting where appropriate, and develop transparent value dossiers that align clinical benefits with economic considerations. Taken together, these actions will support sustainable adoption while protecting patient access and promoting high-quality care.
A transparent multi-method research framework incorporating expert interviews, literature synthesis, real-world evidence analysis, and supply chain and policy review to ensure robust conclusions
The research approach combines multiple complementary methods to produce a comprehensive and defensible evidence base. Primary research consisted of structured interviews with clinical experts, specialty pharmacists, payers, and supply chain managers to capture frontline perspectives on diagnosis, treatment selection, and access barriers. These qualitative insights were triangulated with an exhaustive review of peer-reviewed literature, regulatory filings, clinical trial portals, and publicly available treatment guidelines to ensure alignment with the most current scientific and regulatory context.
In addition, real-world data sources and anonymized treatment registries were analyzed to identify patterns in therapy utilization, treatment discontinuation, and care setting preferences. Supply chain mapping and policy analysis were used to evaluate the implications of trade measures and procurement dynamics. Throughout the process, methodological rigor was maintained via transparent inclusion criteria, interviewer training, and consistency checks, and findings were validated in follow-up consultations with independent clinicians and payer advisors to mitigate bias and confirm practical relevance.
A concise synthesizing conclusion highlighting coordinated clinical, commercial, and operational priorities required to translate scientific advances into equitable patient outcomes
In conclusion, the Castleman disease landscape is at an inflection point where improved biological understanding and targeted therapies are intersecting with heightened payer scrutiny and supply chain complexity. Clinical practice is evolving toward precision-informed regimens supported by stronger evidence generation and integrated care models. At the same time, trade dynamics and procurement pressures are prompting stakeholders to rethink sourcing, manufacturing, and distribution approaches to preserve access and manage cost volatility.
Moving forward, success will require coordination across clinical, commercial, and operational domains. By investing in diagnostic standardization, durable evidence generation, resilient supply chains, and payer-aligned access strategies, stakeholders can reduce barriers to care while ensuring that treatments deliver meaningful, lasting benefits for patients. The collective actions of developers, providers, and payers will determine whether the promise of recent scientific advances translates into consistent, equitable outcomes for people living with Castleman disease.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
199 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Clinical trial advancements in investigational siltuximab biosimilars expanding treatment options for multicentric Castleman disease
- 5.2. Growing adoption of precision medicine approaches leveraging biomarkers to tailor Castleman disease therapy regimens
- 5.3. Rising investment in small molecule inhibitors targeting JAK-STAT signaling for refractory Castleman disease management
- 5.4. Increasing collaboration between academic centers and biopharma firms accelerating novel Castleman disease drug development
- 5.5. Regulatory approvals of next generation anti–IL-6 receptor agents transforming treatment landscape for Castleman patients
- 5.6. Enhanced patient access programs and reimbursement strategies improving affordability of rare disease therapies
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Castleman Disease Treatment Market, by Treatment Type
- 8.1. Chemotherapy
- 8.1.1. Combination Therapy
- 8.1.2. Monotherapy
- 8.2. Corticosteroids
- 8.2.1. Dexamethasone
- 8.2.2. Prednisone
- 8.3. Siltuximab
- 8.4. Tocilizumab
- 9. Castleman Disease Treatment Market, by Line Of Therapy
- 9.1. First Line
- 9.1.1. Combination Therapy
- 9.1.2. Monotherapy
- 9.2. Later Lines
- 9.3. Second Line
- 10. Castleman Disease Treatment Market, by Distribution Channel
- 10.1. Offline
- 10.2. Online
- 11. Castleman Disease Treatment Market, by End User
- 11.1. Home Care Settings
- 11.1.1. Self Administration
- 11.1.2. Visiting Nurse Services
- 11.2. Hospitals
- 11.3. Specialty Clinics
- 12. Castleman Disease Treatment Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Castleman Disease Treatment Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Castleman Disease Treatment Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. Janssen Sciences Ireland UC
- 15.3.2. EUSA Pharma Ltd
- 15.3.3. Recordati S.p.A
- 15.3.4. Genentech, Inc.
- 15.3.5. F. Hoffmann-La Roche Ltd
- 15.3.6. Pfizer Inc.
- 15.3.7. Incyte Corporation
- 15.3.8. AbbVie Inc.
- 15.3.9. Biogen Inc.
- 15.3.10. Senhwa Biosciences, Inc.
- 15.3.11. Cylene Pharmaceuticals, Inc.
- 15.3.12. Summit Therapeutics Inc.
- 15.3.13. Bristol-Myers Squibb Company
- 15.3.14. Novartis AG
- 15.3.15. Amgen Inc.
- 15.3.16. Takeda Pharmaceutical Company Limited
- 15.3.17. Swedish Orphan Biovitrum AB
- 15.3.18. Regeneron Pharmaceuticals, Inc.
- 15.3.19. Sandoz International GmbH
- 15.3.20. Every Cure Foundation
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
